T-cell depletion of allogeneic peripheral blood stem cells

Bailliere's Best Practice in Clinical Haematology

Volumn 12, Issue 1-2, 1999, Pages 87-98

  Link, Hartmut ^a  

^a Westpfalz Medical Centre   (Germany)

Author keywords

Allogeneic transplantation; Blood progenitor cell transplantation; CD34+ stem cells

Indexed keywords

CD34 ANTIGEN;

ALLOGRAFT; APHERESIS; CELL DENSITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA TYPING; HUMAN; HUMAN CELL; INHERITANCE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; STEM CELL; T LYMPHOCYTE;

EID: 0032709670     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1053/beha.1999.0009     Document Type: Article

References (67)

1. Schmitz N, Dreger P, Suttorp M et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony stimulating factor). Blood 1995; 85: 1666-1672.
2. Körbling M, Przepiorka D, van Besien K et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 1995; 85: 1659-1665.
3. Bensinger WI, Weaver CH, Appelbaum FR et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Blood 1995; 85: 1655-1658.
4. + blood cells. Blood 1995; 86: 2500-2508.
5. Schmitz N, Bacigalupo A, Labopin M et al. Transplantation of allogeneic peripheral blood progenitor cells - the EBMT experience. Bone Marrow Transplantation 1996; 17 (supplement 2): S40-S46.
6. Goulmy E, Schipper R, Pool J et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. New England Journal of Medicine 1996; 334: 281-285.
7. Kernan NA, Dupont B. Minor histocompatibility antigens and marrow transplantation. New England Journal of Medicine 1996; 334: 323-324.
8. Ferrara JL & Deeg HJ. Graft-versus-host disease. New England Journal of Medicine 1991; 324: 667-674.
9. Vogelsang GB & Hess AD. Graft-versus-host disease: new directions for a persistent problem. Blood 1994; 84: 2061-2067.
10. Verdonck LF, de Gast GC, van Heugten HG & Dekker AW. A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation. Blood 1990; 75: 776-780.
11. Kernan NA, Collins NH, Juliano L et al. Clonable T lymphocytes in T cell-depleted bone marrow transplants correlate with development of graft-v-host disease. Blood 1986; 68: 770-773.
12. Wagner JE, Santos GW, Noga SJ et al. Bone marrow graft engineering by counterflow centrifugal elutriation: results of a phase I-II clinical trial. Blood 1990; 75: 1370-1377.
13. Theobald M, Nierle T, Bunjes D et al. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. New England Journal of Medicine 1992; 327: 1613-1617.
14. Schwarer AP, Jiang YZ, Brookes PA et al. Frequency of anti-recipient alloreactive helper T-cell precursors in donor blood and graft-versus-host disease after HLA-identical sibling bone-marrow transplantation. Lancet 1993; 341: 203-205.
15. Pan L, Delmonte J Jr., Jalonen CK & Ferrara JL. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes donor T lymphocytes toward type-2 cytokine production and reduces severity of experimental graft-versus-host disease. Blood 1995; 86: 4422-4429.
16. Storb R, Prentice RL, Sullivan KM et al. Predictive factors in chronic graft-versus-host disease in patients with aplastic anemia treated by marrow transplantation from HLA-identical siblings. Annals of Internal Medicine 1983; 98: 461-465.
17. Sullivan KM, Storb R, Buckner CD et al. Graft-versus-host disease as adoptive immunotherapy in patients with advanced hematologic neoplasms. New England Journal of Medicine 1989; 320: 828-834.
18. Kolb HJ, Schattenberg A. Goldman JM et al. Graft versus leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2050.
19. Beelen DW, Ottinger HD. Elmaagacli A et al. Transplantation of filgrastim-mobilized peripheral blood stem cells from HLA-identical sibling or alternative family donors in patients with hematologic malignancies: a prospective comparison on clinical outcome, immune reconstitution, and hematopoietic chimerism. Blood 1997; 90: 4725-4735.
20. + T cells in a murine model of MHC-matched peripheral blood progenitor cell transplantation (PBPCT). Experimental Hematology 1998; 26: 93-99.
21. Apperley JF, Mauro FR, Goldman JM et al. Bone marrow transplantation for chronic myeloid leukaemia in first chronic phase: importance of a graft-versus-leukaemia effect. British Journal of Haematology 1988; 69: 239-245.
22. Goldman JM, Gale RP, Horowitz MM et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: Increased risk for relapse associated with T-cell depletion. Annals of Internal Medicine 1988; 108: 806-814.
23. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
24. Marmont AM, Horowitz MM. Gale RP et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 1991; 78: 2120-2130.
25. Verdonck LF, Dekker AW, de Gast GC et al. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft. Blood 1994; 83: 3090-3096.
26. - alpha beta bone marrow T cells with suppressor activity. Journal of Immunology 1992; 148: 373-380.
27. + cells and T cell depletion by percoll density gradient centrifugation. Bone Marrow Transplantation 1996; 17 (supplement 2): S31-S33.
28. Przepiorka D, Ippoliti C, Panina A et al. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation. Bone Marrow Transplantation 1994; 13: 461-464.
29. Maraninchi D, Biaise D, Rio B et al. Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard-risk leukaemias. Lancet 1987; ii: 175-178.
30. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplantation 1990; 6: 283-289.
31. Papadopoulos EB. Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New England Journal of Medicine 1994; 330: 1185-1191.
32. Andrews RG. Singer JW & Bernstein ID. Monoclonal antibody 12-8 recognizes a 115-kd molecule present on both unipotent and multipotent hematopoietic colony-forming cells and their precursors. Blood 1986; 67: 842-845.
33. + marrow cells engraft lethally irradiated baboons. Journal of Clinical Investigation 1988; 81: 951-955.
34. Corringham RET & Ho AD. Rapid and sustained allogeneic transplantation using immunoselected CD34+ selected peripheral blood progenitor cells mobilized by recombinant granulocyte- and granulocyte-macrophage colony stimulating factors. Blood 1995; 86: 2052-2054.
35. + cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687-1691.
36. Negrin RS, Kusnierz-Glaz CR, Still BJ et al. Transplantation of enriched and purged peripheral blood progenitor cells from a single apheresis product in patients with non-Hodgkin's lymphoma. Blood 1995; 85: 3334-3341.
37. Preijers F, Schattenberg A, Ruijs P et al. The use of counterflow centrifugation elutriation (CCE) to deplete T cells from allogeneic peripheral blood stem cell (PBSC) grafts Bone Marrow Transplantation 1996; 17 (supplement 2): S74, A35 (abstract).
38. + blood cells additionally T-cell depleted with Campath-IH. Bone Marrow Transplantation 1997; 19 (supplement 1): O600 (abstract).
39. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
40. Barrett AJ & Malkovska V. Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. British Journal of Haematology 1996; 934: 754-761.
41. Butturini A, Bortin MM & Gale RP. Graft-versus-leukemia following bone marrow transplantation. Bone Marrow Transplantation 1987; 2: 233-242.
42. Walter E. Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine 1995; 333: 1038-1044.
43. + cells immunoselected from G-CSF mobilized peripheral blood progenitor cells of the marrow donor. Bone Marrow Transplantation 1994; 14: 791-797.
44. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
45. + cells and unseparated peripheral blood progenitor cells mediate identical hematopoietic engraftment after high-dose VP16, ifosfamide, carboplatin, and epirubicin. Blood 1994; 84: 1421-1426.
46. Shpall EJ, Jones RB, Bearman SI et al. Transplantation of enriched CD34-positive autologous marrow into breast cancer patients following high-dose chemotherapy: influence of CD34-positive peripheral-blood progenitors and growth factors on engraftment. Journal of Clinical Oncology 1994; 12: 28-36.
47. Weaver CH, Buckner CD, Longin K et al. Syngeneic transplantation with peripheral blood mononuclear cells collected after the administration of recombinant human granulocyte colony-stimulating factor. Blood 1993; 82: 1981-1984.
48. + blood cells. Blood 1996; 87: 4903-4909.
49. Link H, Boogaerts M, Fauser AA et al. A controlled trial of recombinant human erythropoietin after bone marrow transplantation. Blood 1994; 84: 3327-3335.
50. Ferrara J, Lipton J, Hellman S et al. Engraftment following T-cell depleted marrow transplantation: I. The role of major and minor histocompatibility barriers. Transplantation 1987; 43: 461-467.
51. Aversa F, Tabilio A, Terenzi A et al. Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994; 84: 3948-3955.
52. Kaufman CL, Colson YL, Wren SM et al. Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84: 2436-2446.
53. Uharek L, Gassmann W, Glass B et al. Influence of cell dose and graft-versus-host reactivity on rejection rates after allogeneic bone marrow transplantation. Blood 1992; 79: 1612-1621.
54. Bachar-Lustig E. Rachamim N, Li HW et al. Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nature Medicine 1995; 1: 1268-1273.
55. + blood stem cells from HLA-haploidentical parental donors for transplantation in SCID. Bone Marrow Transplantation 1996; 17 (supplement I): S112, A494 (abstract).
56. + cells from an HLA-identical unrelated donor. Bone Marrow Transplantation 1995; 16: 719-722.
57. + cell in healthy sibling donors. British Journal of Haematology 1996; 93 (supplement 2): 275, A1038 (abstract).
58. Johnson BD, Drobyski WR & Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplantation 1993; 11: 329-336.
59. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261-1268.
60. + cells of peripheral blood (PBSC) and marrow (BM) from related donors results in prompt engraftment and low incidence of GVHD in recipients undergoing allogeneic transplantation. Blood 1995; 86 (supplement 1): 389a, A1543 (abstract).
61. + selected cells. Leukemia and Lymphoma 1997; 25: 145-151.
62. + peripheral blood progenitor cells (PBPC) for allogeneic transplantation. British Journal of Haematology 1996; 93 (supplement 2): 164 (abstract).
63. + selected progenitor cells from matched related donors: results of a clinical phase I/II study. Blood 1995; 86 (supplement 1): 290a, A1148 (abstract).
64. + peripheral blood stem cells (PBSC) in older patients with advanced hematologic malignancy: Blood 1995; 86 (supplement 1): 389a, A1545 (abstract).
65. + selected stem cell transplants in patients with advanced leukemia from 3 loci mismatched family donors. Blood 1995; 86 (supplement 1): 937a, A3736 (abstract).
66. + blood stem cells and bone marrow for HLA nonidentical transplantation in children with leukaemia Blood 1995; 86 (supplement 1): 92a, A354 (abstract).
67. + cells from haploidentical parental donors for relapsed acute leukemia in children. Blood 1995; 86 (supplement 1): 291a (abstract).